Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis.
Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for treating ALS. The trial is slated to enroll approximately 200 patients at 6 sites in the US, with the primary outcome being an ALSFR-S score responder analysis.
Read the whole story on our sister site, Drug Delivery Business
The post Brainstorm Cell Therapeutics wins $16m grant for pivotal NurOwn ALS study appeared first on MassDevice.
from MassDevice http://ift.tt/2uipgbg
Cap comentari:
Publica un comentari a l'entrada